Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application

Abstract

The invention is related to the medicinal means of treatment of diseases, traumas, as well as consequences of traumas of the central nervous system, and can be also used as a means of stimulating neurons regeneration. There is proposed a peptide glutamyl-aspartyl-arginine with general formula H-GIu-Asp-Arg-OH sequence 1 [SEQ ID NO:1] capable of stimulating the regeneration of neurons. There is also proposed a pharmaceutical composition stimulating the regeneration of neurons containing peptide glutamyl-aspartyl-arginine with general formula H-GIu-Asp-Arg-OH sequence 1 [SEQ ID NO:1] as its active base, as well as a pharmaceutically acceptable carrier. There is proposed a method of stimulating the regeneration of neurons consisting in the administration to a patient of the pharmaceutical composition, containing peptide glutamyl-aspartyl-arginine with general formula H-Glu-Asp-Arg-OH sequence 1 [SEQ ID NO:1] as its active base, in the dose of 0.01-100 μg/kg of body weight at least once a day during a period necessary for attaining the therapeutic effect, such administration being performed parenterally.

1 - 6 . (canceled) 
     
     
         7 . A peptide of the formula H-Lys-Glu-Asp-OH. 
     
     
         8 . The pharmaceutical composition comprising the peptide of  claim 7  and a pharmaceutically acceptable carrier. 
     
     
         9 . The pharmaceutical composition according to  claim 8 , which is a parenteral formulation. 
     
     
         10 . A method of stimulating regeneration of central nervous system neurons, which consists in administering to the patient a composition containing peptide glutamyl-aspartyl-arginine of the formula H-Glu-Asp-Arg-OH as its active base in the dose of 0.01-100 μg/kg of body weight at least once a day during a period necessary for attaining the therapeutic effect. 
     
     
         11 . The method of  claim 10 , wherein the composition is administered parenterally.